Skip to main content
Journal cover image

Immunotherapy advances for glioblastoma.

Publication ,  Journal Article
Reardon, DA; Freeman, G; Wu, C; Chiocca, EA; Wucherpfennig, KW; Wen, PY; Fritsch, EF; Curry, WT; Sampson, JH; Dranoff, G
Published in: Neuro Oncol
November 2014

Survival for patients with glioblastoma, the most common high-grade primary CNS tumor, remains poor despite multiple therapeutic interventions including intensifying cytotoxic therapy, targeting dysregulated cell signaling pathways, and blocking angiogenesis. Exciting, durable clinical benefits have recently been demonstrated for a number of other challenging cancers using a variety of immunotherapeutic approaches. Much modern research confirms that the CNS is immunoactive rather than immunoprivileged. Preliminary results of clinical studies demonstrate that varied vaccine strategies have achieved encouraging evidence of clinical benefit for glioblastoma patients, although multiple variables will likely require systematic investigation before optimal outcomes are realized. Initial preclinical studies have also revealed promising results with other immunotherapies including cell-based approaches and immune checkpoint blockade. Clinical studies to evaluate a wide array of immune therapies for malignant glioma patients are being rapidly developed. Important considerations going forward include optimizing response assessment and identifiying correlative biomarkers for predict therapeutic benefit. Finally, the potential of complementary combinatorial immunotherapeutic regimens is highly exciting and warrants expedited investigation.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Neuro Oncol

DOI

EISSN

1523-5866

Publication Date

November 2014

Volume

16

Issue

11

Start / End Page

1441 / 1458

Location

England

Related Subject Headings

  • Oncology & Carcinogenesis
  • Immunotherapy
  • Humans
  • Glioblastoma
  • Animals
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1109 Neurosciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Reardon, D. A., Freeman, G., Wu, C., Chiocca, E. A., Wucherpfennig, K. W., Wen, P. Y., … Dranoff, G. (2014). Immunotherapy advances for glioblastoma. Neuro Oncol, 16(11), 1441–1458. https://doi.org/10.1093/neuonc/nou212
Reardon, David A., Gordon Freeman, Catherine Wu, E Antonio Chiocca, Kai W. Wucherpfennig, Patrick Y. Wen, Edward F. Fritsch, William T. Curry, John H. Sampson, and Glenn Dranoff. “Immunotherapy advances for glioblastoma.Neuro Oncol 16, no. 11 (November 2014): 1441–58. https://doi.org/10.1093/neuonc/nou212.
Reardon DA, Freeman G, Wu C, Chiocca EA, Wucherpfennig KW, Wen PY, et al. Immunotherapy advances for glioblastoma. Neuro Oncol. 2014 Nov;16(11):1441–58.
Reardon, David A., et al. “Immunotherapy advances for glioblastoma.Neuro Oncol, vol. 16, no. 11, Nov. 2014, pp. 1441–58. Pubmed, doi:10.1093/neuonc/nou212.
Reardon DA, Freeman G, Wu C, Chiocca EA, Wucherpfennig KW, Wen PY, Fritsch EF, Curry WT, Sampson JH, Dranoff G. Immunotherapy advances for glioblastoma. Neuro Oncol. 2014 Nov;16(11):1441–1458.
Journal cover image

Published In

Neuro Oncol

DOI

EISSN

1523-5866

Publication Date

November 2014

Volume

16

Issue

11

Start / End Page

1441 / 1458

Location

England

Related Subject Headings

  • Oncology & Carcinogenesis
  • Immunotherapy
  • Humans
  • Glioblastoma
  • Animals
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1109 Neurosciences